# Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Study · id `cardio:ct-nct01031680` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01031680](<https://clinicaltrials.gov/study/NCT01031680>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01031680

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 922 participants.

## Technical summary

Registry record NCT01031680. Randomized; quadruple masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2013-08-23.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 922 participants (enrolled count; ClinicalTrials.gov record NCT01031680, source copy `cardio:ctgov-nct01031680-2013-10-29`, retrieved 2026-10-26)
- Start date: 2010-02 (registry gives no type) (ClinicalTrials.gov record NCT01031680, source copy `cardio:ctgov-nct01031680-2013-10-29`, retrieved 2026-10-26)
- Primary completion: 2011-05 (actual) (ClinicalTrials.gov record NCT01031680, source copy `cardio:ctgov-nct01031680-2013-10-29`, retrieved 2026-10-26)
- Completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01031680, source copy `cardio:ctgov-nct01031680-2013-10-29`, retrieved 2026-10-26)
- Results first posted: 2013-08-23 (ClinicalTrials.gov record NCT01031680, source copy `cardio:ctgov-nct01031680-2013-10-29`, retrieved 2026-10-26)
- Countries: United States; Argentina; Canada; Germany; Romania; Slovakia; Spain; Taiwan; Vietnam (ClinicalTrials.gov record NCT01031680, source copy `cardio:ctgov-nct01031680-2013-10-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01031680-2013-10-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
- Condition: Type 2 Diabetes Mellitus
- Condition: Cardiovascular Disease
- Condition: Hypertension
- Condition: Inadequate Glycaemic Control
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension (`cardio:pubmed-25852208`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 52dbda51c6cff4dbe0eddbc41986b2952e369c55212d5c7f22a6bc3713f2046e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
